Latest Paclitaxel Stories
SAN ANTONIO, December 11, 2014 /PRNewswire/ -- - The first study in the world combining Reparixin, an oral inhibitor of CXCR1/2, with standard
SAN DIEGO, Dec. 3, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
LAUSANNE, Switzerland, November 18, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs
SAN DIEGO, Nov. 12, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), today announced that Dr.
CYRAMZA now approved both as a single-agent treatment and in combination with chemotherapy INDIANAPOLIS, Nov.
Study Failed to Meet Secondary Endpoint of Overall Survival THOUSAND OAKS, Calif., Nov.
- ABRAXANE plus gemcitabine to be PBS listed for Australian patients with metastatic pancreatic cancer from 1 November MELBOURNE, Australia, Oct.
HARBIN, China, Oct. 30, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc.
Trial will test the potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer ST. HELIER, Jersey, Oct.
SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.